I
9.58
-0.52 (-5.15%)
| Penutupan Terdahulu | 10.10 |
| Buka | 10.18 |
| Jumlah Dagangan | 676,581 |
| Purata Dagangan (3B) | 1,396,945 |
| Modal Pasaran | 1,194,204,416 |
| Harga / Pendapatan (P/E TTM) | 479.00 |
| Harga / Jualan (P/S) | 1.31 |
| Harga / Buku (P/B) | 145.25 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Apr 2025 |
| Margin Keuntungan | -5.30% |
| Margin Operasi (TTM) | 25.56% |
| EPS Cair (TTM) | -0.050 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -6.30% |
| Nisbah Semasa (MRQ) | 0.880 |
| Aliran Tunai Operasi (OCF TTM) | 135.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 265.50 M |
| Pulangan Atas Aset (ROA TTM) | 12.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
| Stok | Indivior PLC | Menurun | - |
AISkor Stockmoo
1.3
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.25 |
|
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.01% |
| % Dimiliki oleh Institusi | 80.59% |
| Julat 52 Minggu | ||
| Median | 13.00 (35.70%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 06 Mar 2025 | 13.00 (35.70%) | Beli | 9.89 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 May 2025 | Pengumuman | New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy |
| 24 Apr 2025 | Pengumuman | Indivior Announces Q1 2025 Financial Results |
| 04 Mar 2025 | Pengumuman | Indivior Announces Further Changes to Board of Directors |
| 27 Feb 2025 | Pengumuman | Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer |
| 24 Feb 2025 | Pengumuman | Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection |
| 20 Feb 2025 | Pengumuman | Indivior Announces FY and Q4 2024 Financial Results |
| 12 Feb 2025 | Pengumuman | Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |